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ABSTRACT:  
Rare lethal disease gene identification remains a challenging issue, but it is amenable to 
new techniques in high-throughput sequencing (HTS). Cerebral proliferative glomeruloid 
vasculopathy (PGV), or Fowler syndrome, is a severe autosomal recessive disorder of 
brain angiogenesis, resulting in abnormally thickened and aberrant perforating vessels 
leading to hydranencephaly. In 3 multiplex consanguineous families, genome-wide SNP 
analysis identified a locus of 14 Mb on chromosome 14. In addition, 280 consecutive 
SNPs were identical in two Turkish families unknown to be related, suggesting a founder 
mutation reducing the interval to 4,1Mb. To identify the causative gene, we then 
specifically enriched for this region with sequence capture and performed HTS in a 
proband of 7 families. Due to technical constraints related to the disease, the average 
coverage was only 7X. Nonetheless, iterative bioinformatic analyses of the sequence data 
identified mutations and a large deletion in the FLVCR2 gene, encoding a twelve 
transmembrane domain-containing putative transporter. A striking absence of alpha-
smooth muscle actin immunostaining in abnormal vessels in fetal PGV brains, suggests a 
deficit in pericytes, cells essential for capillary stabilisation and remodelling during brain 
angiogenesis. This is the first lethal disease-causing gene to be identified by 
comprehensive HTS of an entire linkage interval.   
  
Key words Fowler syndrome, cerebral proliferative vasculopathy, FLVCR2, 
hydranencephaly, fetal lethality, arthrogryposis 
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INTRODUCTION  
Cerebral proliferative glomeruloid vasculopathy (PGV) is a severe autosomal recessive 
disorder of brain angiogenesis, resulting in abnormally thickened and aberrant perforating 
vessels, forming glomeruloids with inclusion-bearing endothelial cells. This peculiar 
vascular malformation was delineated by Fowler in 1972 in relation to a stereotyped, 
lethal fetal phenotype (OMIM 225790), associating hydranencephaly and hydrocephaly 
with limb deformities (Fowler, et al., 1972). PGV disrupts the developing central nervous 
system (CNS) but the reason for which abnormal angiogenesis is restricted to the CNS 
parenchyme remains unknown. Arthryogryposis, when present, appears to be a secondary 
result of CNS motoneuron degeneration, itself one potential outcome of perfusion failure. 
Since its earliest description, 42 PGV cases from 26 families have been reported on the 
basis of histological criteria (Bessieres-Grattagliano, et al., 2009; Williams, et al. 2010).  
 Identification of a causative gene for a very rare lethal syndrome is a challenge at many 
levels. The first issue is to find a family that allows the identification of a linkage 
interval. Such an interval may contain too many genes to make the classical subsequent 
strategy practical, consisting in designing primers that will permit sequencing of each 
exon of all the genes of the region. The second difficulty is that sequencing of all the 
exons is sometimes vain in light of the growing number of non-coding regions identified 
as pathogenic alleles (Benko, et al., 2009; Kleinjan and van Heyningen, 2005; Lettice, et 
al., 2003). Finally, for prenatally lethal syndromes such as PGV, technical constraints 
such as poor quality genomic DNA samples are added. Recent advances in biotechnology 
permit the sequencing of all the DNA, including the non-coding regions, in most genomic 
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intervals. After homozygosity mapping of a 4.1 Mb region, we applied targeted genome 
capture by using a NimbleGen array and high-throughput Roche 454 GS FLX sequencing 
to the genomic DNA of the proband of 6 families. Bioinformatic analysis of the data 
allowed us to identify FLVCR2 (MIM 610865) as the gene responsible for Fowler 
syndrome (FS). High-throughput sequencing (HTS) generated false positive and false 
negative results, in part due to insufficient sequencing coverage, and unless care is taken, 
these can engender the risk of missing mutations during the analysis.  
  
MATERIALS AND METHODS  
Patients : The 7 families analysed have been previously reported (Families I to VII 
(Bessieres-Grattagliano, et al., 2009)). Genomic DNA was extracted from frozen tissue or 
cultured amniocyte cells in fetal cases and from peripheral blood samples for parents and 
unaffected siblings. 
Genome linkage screening and linkage analysis: Genome-wide homozygosity mapping 
was performed using 250K Affymetrix SNP arrays in 5 affected and 3 unaffected 
individuals of two Turkish and one French multiplex, consanguineous families. Data 
were evaluated by calculating multipoint lod scores across the whole genome using 
MERLIN software, assuming recessive inheritance with complete penetrance.  
NimbleGen Sequence capture and high-throughput sequencing: A custom sequence 
capture array was designed and manufactured by Roche NimbleGen (Madison, WI, 
USA). 21 micrograms of genomic DNA was used for sequence-capture in accordance 
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with the manufacturer’s instructions (Roche NimbleGen) and a final amount of 3 
micrograms of amplified enriched DNA was used as input for generating a ssDNA 
library for HTS; 25% lane of a Roche 454 GS FLX sequencer with Titanium reagents) 
yielding 135 Mb of sequence data per sample.  
Capillary sequencing of FLVCR2 : Primers were designed in introns flanking the 10 
exons using the “Primer 3” program (http://fokker.wi.mit.edu/primer3/input.htm) and are 
listed in Supp. Table S2. PCR were all performed in the same conditions, with a 
touchdown protocol consisting of denaturation for 30s at 96°C, annealing for 30s at a 
temperature ranging from 64°C to 50°C (decreasing 1° during 14 cycles, then 20 cycles at 
50°) and extension at 72°C for 30s. PCR products were treated with Exo-SAP IT (AP 
Biotech), and both strands were sequenced with the appropriate primer and the “BigDye” 
terminator cycle sequencing kit (Applied Biosystems Inc.) and analyzed on ABI3130 
automated sequencers. Mutation numbering is based on cDNA reference sequence 
NM_017791.  
Immunohistochemistry : Immunohistochemistry was carried out on six micrometer 
selected sections using antisera directed against smooth muscle actin (diluted 1:800). 
Immunohistochemical procedures included a classical microwave pre-treatment protocol 
in citrate buffer to aid antigen retrieval. Incubations were performed for one hour at room 
temperature, using the TECHMATE system (DAKOPATTS-Trappes-France). After 
incubation, histological slides were processed using the LSAB detection kit 
(DAKOPPATTS-Trappes-France). Peroxidase was visualized by means of either 3-3' 
diaminobenzidine or amino-ethyl carbazole. 
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RESULTS  
We have collected DNA from fetuses of 7 families reported earlier (Families I to VII 
(Bessieres-Grattagliano, et al., 2009)). All 14 fetal cases bore the brain-specific 
angiogenic anomalies characteristic of PGV, resulting in thickened and aberrant 
perforating vessels and glomeruloids, as exemplified in Figure 1A. Endothelial cells 
(ECs) were positive for CD34 in both control fetal brains (Figure 1B) and in the tortuous 
glomerular capillaries (Figure 1C). VEGF-A, while not normally expressed by small 
brain capillaries (Figure 1D), was strikingly found in the glomerular ECs of PGV fetuses 
(Figure 1E arrowhead). Like normal Ecs though, PGV ECs expressed VEGFR2 and, 
weakly, Glut-1 (not shown). CD68, characteristic of macrophages, was completely absent 
(data not shown). Numerous GFAP-positive astrocytes were observed throughout the 
cerebral mantle, with immunoreactive endfeet justaposed to glomeruloids (Figure 1F). An 
antibody to alpha-smooth muscle actin (aSMA) stained vessels within the outer 
leptomeninges and the walls of perforating vessels in normal fetal brains (Figure 1G). In 
contrast, although PGV meningeal vessels had similar aSMA expression, the dysplastic 
intraparenchymous vessels were irregularly stained, if at all (Figure 1H), while most 
glomeruloid vessels were negative for aSMA (Figure 1I).  
To find the molecular basis for this phenotype, we first undertook a genome-wide SNP 
analysis using an Affymetrix 250K SNP chip with 5 affected and 3 unaffected members 
of two Turkish and one French multiplex, consanguineous families. Informed consent 
was obtained from all patients and their relatives; clinical data of all families have 
previously been reported (Bessieres-Grattagliano, et al., 2009). Genome-wide linkage 
Page 8 of 31
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 8 
analysis conducted with the MERLIN program revealed a 13 Mb genomic region on 
chromosome 14 from rs10151019 to rs12897284, with a lodscore of 5.4. Moreover, four 
affected sibs from the two Turkish families shared the same alleles for 280 consecutive 
SNPs, suggesting a founder effect and reducing the interval to 4.1 MB, from rs2803958 
to rs11159220. These two families originated from villages 12 km apart in 
Khramanmaraps (central Turkey). Microsatellite marker analysis further confirmed the 
same disease allele in both families, and showed linkage in 3 additional families (Figure 
2).   
To identify the causative gene, we applied array-based sequence capture of the complete 
4.1 MB region followed by high-throughput sequencing. DNA from one proband of 6 
families, the heterozygous mother from family I, and a healthy brother not carrying the 
at-risk allele were selected (Figure 2). Coverage varied from 2X to 12X in individuals 
depending on the integrity of their DNA (Table 1), with an average coverage depth of 
7X; 60% (851,147) of the enriched reads were located on the targeted regions. Only 25% 
of the targeted regions reached 10X coverage depth.  
The number of the detected variations was too large to handle them manually. To 
facilitate the analysis of these variations a specific genome browser was set up to 
visualise the locations of variations on the genome, and at the same time an analysis tool 
has been developed. This analysis tool applied a series of filters to the identified 
variations. These filters were based on the following criteria: 1) the quality of the 
sequence variant measured as the number of reads that detected the variant 2) the 
presence or absence of variants in public databases such as dbSNP and HapMap. 3) the 
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presence or absence of the variants among the studied samples 4) annotation of the 
sequence variants based on their location (intron, exon, etc ...) and the characteristics of 
the resulting change such as synonymous, non-synonymous or stop mutation. Filtered 
results were visualised in an interactive table permitting us to sort and analyse the results. 
Thus, initial analysis of the sequence data that met an arbitrary threshold of at least three 
reads, of which at least one was required to be in the opposing orientation, detected a 
total of 23,262 variations, 17,031 of which were on chromosome 14 (73%, Table S1). Of 
these, 3,457 variants were found to not correspond to known SNPs, and were absent from 
the normal control individual (E). After initial exclusion of non-exonic and synonymous 
variants, 42 variants in 29 candidate genes remained. In 20 of these genes, a single 
variation was found in one individual, while two and three variations were found in six 
and two genes, respectively (Figure 3).  
  
FLVCR2 was the only gene with variations identified in four out of seven individuals. In 
addition, careful examination of the FLVCR2 locus in the proband of family II revealed a 
homozygous deletion of exons 2 to 10, as the absence of both nucleotide variations and 
reads over a 46.8 KB genomic region (Figure 4A). The deletion was confirmed to 
segregate in families I and II, and cloning of the breakpoints revealed the inclusion of the 
last two exons of the neighbouring C14orf1 gene, with no repeated DNA sequences at the 
boundaries. It is noteworthy that this deletion was not detected by Affymetrix 250K SNP 
chip. Indeed, only one SNP was located in the non-deleted portion of intron 1. Direct 
sequencing of the 10 exons of FLVCR2 (Supp. Table S1), identified mutations in two 
additional families (Table 1), such that mutant FLVCR2 alleles were identified in each of 
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the 7 families studied (5 homozygotes and 2 compound heterozygotes; Table 1 and 
Figure 4B).  
Reasons for false-negative results using HTS approaches are summarized in Table 1, and 
emphasize the need for complementary confirmation. In particular, in family IV, a second 
heterozygous mutation was found by direct resequencing, although it had an apparently 
homozygous mutation as indicated by the HTS analysis. In family III, the homozygous 
mutation found with Sanger sequencing had only been read 2 times in the HTS and had 
thus been excluded by the stringency of the filter. As a third example, the second 
heterozygous mutation in family VII had been read 4 times but was excluded for 
unidirectionality. Interestingly, in family VI, not known to be consanguineous, the 
identical nonsense mutation was found in the 3 affected sibs (homozygous in fetuses and 
heterozygous in parents), suggesting more distant consanguinity or a founder effect.  
FLVCR2 is a member of the major facilitator sup rfamily (MFS) of transporter proteins, 
that shuttle small molecules in response to ion gradients (Pao, et al., 1991). Like other 
MFS members, FLVCR2 is predicted to contain 12 membrane-spanning segments and six 
extracellular loops. As shown in figure 5A, the 3 homozygous mutations are predicted to 
alter an amino-acid localized to one transmembrane domain (TM) : TM2 in family VI, 
TM8 in family III and TM10 in family V. In family IV, one of the 2 mutations alters an 
amino-acid predicted to be localized in TM8 and the other in the intracellular loop 5.  
Amino acid sequence alignment for FLVCR2 from 10 different species showed that T430 
and G412 have been conserved since our common ancestor with C. elegans, whereas R84 
has been conserved in common with D. melanogaster (Figure 5B). T352R and L398V 
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alter residues less evolutionary conserved, especially L398V. However, those mutations 
are absent from both the dbSNP and the 1000 Genome database not yet integrated in 
dbSNP. While the L398V mutation was predicted to be benign by the Polyphen algorithm 
(http://genetics.bwh.harvard.edu/pph/), the T352R mutation as well as the other missense 
mutations identified in this study were predicted to be damaging to protein function. 
Thus, the pathogenicity of these two last mutations is likely but not totally proven. In 
total, eight different mutations including one nonsense mutation (homozygous in family 
VI), six missense mutations, and one homozygous deletion in two families (I and II) have 
been found in FLVCR2. 
 
DISCUSSION   
PGV is a very rare and lethal genetic condition. Since its first description, 42 cases from 
26 families have been reported on the basis of histological criteria of PGV (Bessieres-
Grattagliano, et al., 2009; Williams, et al., 2010). In the 16 fetuses of our series born to 
eight unrelated families, neuropathological analysis defined a diffuse form of 
encephaloclastic prolifrative vasculopathy (EPV), affecting the entire CNS and resulting 
in classical PGV with pterygia and a severe fetal akinesia deformation sequence in 14 
cases. In contrast, two cases from the single family IV presented a more focal form of 
EPV, without spinal cord involvement and subsequent arthrogryposis/pterygia. 
Identification of FLVCR2 mutations in this family suggests that the anteroposterior extent 
of CNS degeneration can be variable, and that PGV may be an extreme phenotype of a 
broader spectrum of proliferative vasculopathies. Stabilization of newly formed capillary 
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sprouts during angiogenesis requires interactions of endothelial cells with mural support 
cells, known as pericytes. The regionally restricted distribution of PGV in family IV 
might be linked to the embryonic lineage of the telencephalic pericytes, of a distinct 
neural crest cell origin from those of the spinal cord (Etchevers, et al., 2001). 
Interestingly, immunostaining for alpha smooth muscle actin (aSMA, a marker for 
mature pericytes) in fetal PGV brains was drastically reduced in the PGV within the CNS 
while normal aSMA expression was found in the leptomeninges (Figure 1I). Further 
studies should elucidate whether this observed effect on pericytes is the primary cause or 
an effect of this disease.  
Recently, FLVCR2 mutations were also reported in 5 families with Fowler syndrome 
(Meyer, et al., 2010), with the same homozygous Thr430Arg mutation in three families, 
and 2 compound heterozygous cases. Interestingely, Thr430Arg is associated with both 
forms of the disease, namely with or without spinal cord involvement, suggesting no 
genotype phenotype correlations. It is noteworthy that the mutation concerned the same 
codon (Thr430) as in our family IV, the only one of our series without spinal cord 
involvement. More recently, Lalonde et al. also reported four FLVCR2 compound 
mutations in 2 FS families with spinal cord involvement ((Lalonde, et al., 2010). 
Interestingly, the only missense mutation predicted to be “benign” in our study (L398V) 
was identified by two distinct approaches in a common case reported by both Lalonde et 
al. and Meyer et al., adding to the likely pathogenicity of this variation. To sum up, 15 
different FLVCR2 mutations (including those described in our study) have now been 
reported in 13 cases: one large deletion, two nonsense mutations, one splice site mutation, 
one insertion/deletion change and 10 missense variations. 
Page 13 of 31
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13 
The FLVCR2 gene encodes a transmembrane protein that belongs to the major facilitator 
superfamily (MFS) of secondary carriers that transport small solutes such as calcium 
(Pao, et al., 1991). It is closely related in both sequence and topology to the better-known 
FLVCR1, sharing 60% amino acid identity (Lipovich, et al., 2002). FLVCR1 has been 
identified as the receptor for a feline leukemia virus (FeLV-C), and like FLVCR2 and 
other MFS members, is predicted to contain 12 membrane-spanning segments and six 
extracellular loops. A single mutation in the sixth extracellular loop is sufficient to confer 
FeLV-C receptor activity on FLVCR2, which does not otherwise bind the native 
virus (Brown, et al., 2006). However, FLVCR2 functions as a receptor for the FeLV-C 
variant FY981 (Shalev, et al., 2009). FLVCR1 is found only in hematopoietic tissues, the 
pancreas and kidney (Tailor, et al., 1999), but rodent Flvcr2 is widely expressed during 
embryonic development, in particular within the CNS and in the vessels of the maturing 
retina, and human FLVCR2, within the fetal pituitary (Brasier, et al., 2004). FLVCR1 has 
been shown to function as a heme exporter, essential for erythropoiesis (Quigley, et al., 
2004). Interestingly, the five glutamate residues in the C-terminal putative coiled-coiled 
domain of FLVCR2, not present in FLVCR1, may serve an analogous function to the 
same ferric ion-binding glutamate sequence in glycine-extended gastrin, by stimulating 
cell proliferation (He, et al., 2004). Based on the cell types in which it is expressed and 
MFS transport of chelated complexes of divalent metal ions, the FLVCR2 transporter 
was postulated to be a gatekeeper for the controlled entry of calcium into target cell types 
(Brasier, et al., 2004). Calcium signalling is involved in virtually all cellular processes 
and its homeostasis is tightly regulated. Angiogenic factors such as VEGF-A and FGF2 
induce a transient increase of endothelial cell intracellular calcium concentrations , which 
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acts as a second messenger to induce proliferation, among other effects (Tomatis, et al., 
2007). Blood vessels are susceptible to responding to angiogenic signals and undergoing 
calcification when their pericytic coverage has been disrupted (Collett and Canfield, 
2005), both of which signs we have observed in PGV patient brain sections.  
HTS of the entire exome has been used so far to identify disease-causing genes in the rare 
Miller and Bartter syndromes, respectively (Choi, et al., 2009; Ng, et al., 2010). Recently, 
targeted exon-specific sequencing within a restricted 40 MB linkage interval allowed the 
identification of an additional gene for Familial Exudative 
Vitreoretinopathy (Nikopoulos, et al., 2010). Our study underlines the use of HTS for the 
coverage of an entire linkage interval with no compelling candidate genes and no 
justification for the exclusion of non-coding regions. Our nested analysis approach led 
rapidly to the identification of a disease-causing gene. While it further demonstrates the 
power of this new technology, it also highlights other potential risks of missing mutations 
during data analyses. The number of patients, diagnostic accuracy and genetic 
homogeneity allowed us to compensate for low capture efficiency due to suboptimal 
DNA quality, and in the future, as the technology develops, furthering the depth of 
coverage should ensure a better distinction of background from true mutations. Finally, 
identification of the gene for Fowler syndrome will permit accurate genetic counselling 
for PGV and prenatal diagnosis, in particular for the late-onset forms of the disease 
without spinal cord involvement.  
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LEGENDS TO TABLE AND FIGURES  
 
Figure 1: Marker analysis in Fowler syndrome fetal brain 
(A) Cortical plate of Fowler syndrome (FS) fetal brain (family IV) showing abnormal perforating 
vessels. Note the characteristic thickened vessels (asterisks), ending in glomeruloid formations 
(arrowheads), often devoid of recognizable lumina. CD34 capillary staining in (B) on a brain 
from a control, stage matched fetus and (C) from a FS fetus (family I) (C). VEGF 
immunostaining arround (D) a brain parenchymal capillary from a control fetus in which it is 
essentially absent, and (E) from a FS fetus in which it appears markedly increased. (F) GFAP 
astroglial immunostaining on a FS fetal brain. Alpha SMA immunostaining of pericytes on (G) a 
brain section from a control fetus versus (H and I) from two FS fetuses.  
Figure 2 : Pedigree and linkage analysis results 
Pedigrees of families included in this study. Arrows indicate individuals for whom DNA was 
available, and arrowheads indicate the samples sequenced by HTS. Homozygosity or linkage was 
analysed by microsatellite markers analysis and confirmed a founder effect by haplotype identity 
in 2 Turkish families (I and II) that were later discovered to carry the same FLVCR2 exon 2 to 10 
deletion. 
Figure 3 : Summary of HTS data analysis 
This diagram illustrates the flowchart of HTS data analysis. After elimination of variants found 
outside of the mapping region (27% of total variants) and those corresponding to known SNPs 
(29% of on-target variants) or shared with the control individual E (50% of on-target variants), 
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HTS identified 54 variants in coding sequences, eight of which were synonymous. The remaining 
46 variants were located in 29 candidate genes, 20 of which were excluded because only one 
variant was identified. Finally, only one gene, FLVCR2 presented 4 variants.  
Figure 4 : FLVCR2 deletion and mutations 
(A) Genome browser view centered on the FLVCR2 locus (ENSG00000119686) showing all 
variations (red dots) and reads coverage (light blue) in individuals A (fetus, family II) and B 
(fetus, family V). Note the absence of variations and reads in individual A, suggesting a 
homozygous deletion of exons 2 to 10, as well as the 2 final exons of the adjacent c14orf1 
transcript (ENSG00000133935). (B) Chromatograms of FLVCR2 homozygous (upper panel) and 
compound heterozygous mutations (lower panel).  
Figure 5: Localisation of mutations in FLVCR2 and conservation of mutated FLVCR2 amino 
acids. 
(A) Localization of mutations on a secondary structure prediction of the FLVCR2 transporter. 
The three homozygous mutations are predicted to alter an amino acid localized in one of the 12 
transmenbrane (TM) domains: p.Y134X is located in TM2, p.L359P in TM8, and p.G412R in 
TM10. Compound heterozygous mutations in family VI alter amino acids at the N-terminal 
cytoplasmic end and in the extracellular loop 5 (blue asterisk). Compound heterozygous 
mutations in family IV alter an amino acid predicted to be localized in TM8 and in the 
intracellular loop 5 (green asterisk).  
(B) Alignment and conservation of mutated FLVCR2 amino acids. Sequences for FLVCR2 from 
10 different species have been aligned using the Multialin tool ("Multiple sequence alignment 
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with hierarchical clustering" (Corpet, 1988). Highly conserved amino acids are represented in 
red, moderately conserved amino acids are in blue and non-conserved ones are in black. Mutated 
amino acids are boxed.  
Table 1 : Analysis of variations by individual and FLVCR2 variations identified by high-
throughput or capillary sequencing.  
E is a healthy brother in family V not carrying the disease allele by haplotyping, and taken as 
healthy control. Mutation numbering is based on cDNA sequence with a ‘c.’ symbol before the 
number, where +1 corresponds to the A of ATG translation codon (codon 1) of the cDNA 
reference sequences (NM_017791). Mutation names were checked by the Mutalyzer program 
(Wildeman, et al., 2008). 
 
Supplementary Table S1: Analysis of total number of variations detected by high-throughput 
sequencing 
 
Supplementary Table S2: Primers and PCR conditions 
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Individual  A (F am II) B  (F am VI) C  (F am VII) D  (F am IV) F  (F am V) G  (F am I) H (F am III) Total
O rigin T urkish F rench F rench F rench Maroccan T urkis h F rench
C overage 8,8X  4X 8,6X  2,3X  11,8X  11,6X  6,6X  7X  
All 2852 1804 2639 823 3067 3841 2005 17 031 
Number of 
Variations
Variations  in E  
removed
1379 790 1154 282 1527 2075 1182
(total) S NP  removed 565 380 608 112 695 872 821
Variations  in E  and 
S NP s  removed
546 300 465 80 569 750 747
Number of 
variations  
T otal 100 74 105 41 87 139 58
on mR NA
Variations  in E  and 
S NP  removed
23 14 17 6 20 26 29
T otal 41 22 44 13 42 60 25
Number of
Variations  in E  and 
S NP  removed 
8 2 4 2 11 12 15
variations  on 
C DS
non synonymous 22 8 23 9 23 28 13
non synonymous  
and S NP  removed
8 2 4 2 9 8 9 42
Next generation 
sequencing
Del E x 2-10 
hmz
c.402C >G , 
p.T yr134S top 
hmz
c.251G >A, p.Arg84His  
htz
c.1056C >G , 
p.T hr352Arg hmz
c.1234G >C , 
p.G ly412Arg 
hmz
(mother) -
F L VC R 2 
variations
C apillary 
sequencing
Del  E x 2-10 
hmz
c.402C >G , 
p.T yr134S top   
hmz
c.251G >A, p.Arg84His  
htz c.1192C >G , 
p.L eu398Val htz 
c.1056C >G , 
p.T hr352Arg htz  
c.1289C >T , 
p.T hr430Met htz 
c.1234G >C , 
p.G ly412Arg 
hmz  
Del  E x 2-10 htz  
in mother
c.1076T >C , 
p.L eu359P ro hmz
C omparis on and 
reas on for 
dis crepancy
confirmation confirmation Arg84His : confirmation 
L eu398Val: 7 reads , 4 
with the mutation, but 
excluded for 
unidirectionality
T 352R : 4 reads  of 
only the mutated 
allele, T 430M:  no 
reads
confirmation D eletion 
confirmed in 
foetuses  (hmz), 
htz in parents
2 reads  of only 
the mutated allele
 
Table 1 : Analysis of variations by individual and FLVCR2 variations identified by next generation or capillary sequencing.   
Mutation numbering is based on cDNA sequence with a ‘c.’ symbol before the number, where +1 corresponds to the A of ATG translation 
codon (codon 1) of the cDNA reference sequences (NM_017791). Mutation names were checked by the Mutalyzer program (Wildeman, et al., 
2008). 
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Heterozygous and homozygous variations ( 20-100% of total reads) All 
variations 
variations 
on chr 14 
% 
on 
Chr 
14 
A + B + C + D + F + G + H 23 262 17 031 73% 
A + B + C + D + F + G + H – E (control) 12 942 8 389 65% 
A + B + C + D + F + G + H – E –HapMap 10 177 5 763 57% 
A + B + C + D + F + G + H – E –dbSNP 6 553 3 457 52% 
A + B + C + D + F + G + H – E –hapMap – dbSNP 6 552 3 457 52% 
A + B + C + D + F + G + H – E –hapMap – dbSNP : mRNA (UTR et CDS) 179 135 75% 
A + B + C + D + F + G + H – E –hapMap – dbSNP : CDS 63 54 85% 
A + B + C + D + F + G + H – E –hapMap – dbSNP : CDS, non synonymous 49 42 85% 
 
Supplementary Table 1 
Analysis of Total Number of variations 
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Primers Sequence PCR size 
FLVCR2-1AF GCCTCTAGTCTCTGTTTCTTCTGG 527 
FLVCR2-1AR TCAGCATGTAGCACATGGAC  
FLVCR2-1BF TGTGCAACTCCTTTCAGTGG 527 
FLVCR2-1BR CAATCACTGCCTGTCACACC  
FLVCR2-2F TCTCTGGTGTTTTGAGGTGAGA 397 
FLVCR2-2R CATGGTATTTCAGGGCATGTT  
FLVCR2-3F TTCACTCAGCCTCAAACAATG  
FLVCR2-3R TAGCTGGGTCCTCTGGATTG  
FLVCR2-4F TGTGTGGCTAAGGGAAGGTT 464 
FLVCR2-4R GGTTGAGATCTAGGGCCATCT  
FLVCR2-5F TCTCCTAGGCCATCTTGTCC 363 
FLVCR2-5R CTTGGCCACTAGGATCTCCA  
FLVCR2-6F GGCAACAGAGCAAGACACTG 382 
FLVCR2-6R TCAGTTAGAAGGCAGCAAAGG  
FLVCR2-7F CCCAGATCATTAGAGGGCCTA 596 
FLVCR2-8R CCAACAAACCCTTCCATCTG  
FLVCR2-9F CCTGTGACCCTTAGGAAATGA 292 
FLVCR2-9R TGCCATGTGTAAGGGATGAA  
FLVCR2-10F TTTCTTGGCTCTCTGGGATG 486 
FLVCR2-10R TATTCTCTGCCACCCTGTCC  
Primers used for cloning the deletion breakpoints of 
families I and II 
FLVCR1-i1 CAGGATAAGCTCCATCATCCTTAC  
C14orf1-3Fex  CTCGGACCTTTGGGATCTG  
 
Supplementary Table 2 
Primers and PCR conditions 
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